Vaccines Market
Vaccines Market - Global Industry Assessment & Forecast
#
Pages:
141
2022
Apr - 2022
VMR-1508
Segments Covered
By
Technology (excluding COVID 19 vaccines) Conjugate vaccines, Inactivated & Subunit vaccines, Live Attenuated vaccines, Recombinant vaccines, Toxoid vaccines, Viral vector vaccines
-
By
Technology (including COVID 19 vaccines) mRNA vaccines, Viral Vector vaccines, Others
-
By
Type Monovalent vaccines, Multivalent vaccines
-
By
Disease Indication Influenza, Pneumococcal diseases, Combination vaccines, HPV, Herpes Zoster, Meningococcal diseases, Rotavirus, MMR, Varicella, Hepatitis, DTP, Polio, COVID 19, Others
-
By
Route of Administration Intramuscular & Subcutaneous administration, Oral administration, Others
-
By
End-user Pediatric vaccines, Adult vaccines
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2022 |
| Forecast
Years:
|
2023 - 2030 |
 Historical
Years:
|
2017 - 2021 |
 Revenue
2022: |
USD 43.80 Billion |
 Revenue 2030:
|
USD 90.52 Billion |
 Revenue CAGR
(2023 - 2030): |
9.50% |
Fastest Growing Region (2023 -
2030)
|
Asia Pacific |
Largest Region (2022):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
| Sr. No. | Offering | Report Coverage |
| 1. | Market Size | In terms of Revenue (USD Million) |
| 2. | Historic Data | 2017 to 2021 |
| 3. | Forecast Data | 2023 to 2030 |
| 4. | Market Drivers, Restraints, Opportunities, & Regional Market Trends | Yes |
| 5. | Market Attractiveness Analysis | Yes |
| 6. | Segment Analysis | Maximum Segments |
| 7. | Regional Coverage | 5 Regions |
| 8. | Country Coverage | Top 22 Countries |
| 9. | Competitive Landscape and Company Market Share Analysis | Yes. Exhaustive information will be provided in two separate chapters of Competitive Landscape and Company Profiles. |
| 10. | Porter’s Five Forces Analysis | Yes. |
| 11. | Value Chain Analysis | Yes |
| 12. | PEST Analysis | Yes |
| 13. | Regulatory Landscape | Yes |
| 14. | Technology Landscape | Yes |
| 15. | COVID-19 Impact Analysis | Yes. Exhaustive information for Key Strategies Undertaken by Companies, Impact Assessment of the COVID-19 Pandemic by Region, along with Short-term and Long-term dynamics. |
| 16. | Top startups to watch out for | Yes |
| 17. | Top 3 Trends to Watch | Yes |
| 18. | Top 3 Strategies Followed by Major Players | Yes |
| 19. | Top 3 Predictions by Vantage Market Research | Yes |
| 20. | Discussion Guide | Yes |
| 21. | Key Primary Respondents - VERBATIM | Yes |
| 22. | Transcripts from the Primary Respondents | Additional Cost USD 1,000 |
| 23. | Others/Miscellaneous | |
FAQ
Frequently Asked Question
What is the global demand for Vaccines in terms of revenue?
-
The global Vaccines valued at USD 43.80 Billion in 2022 and is expected to reach USD 90.52 Billion in 2030 growing at a CAGR of 9.50%.
Which are the prominent players in the market?
-
The prominent players in the market are GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), Pfizer Inc. (US), Sanofi SA (France), CSL Limited (Australia), Emergent BioSolutions Inc. (US), Johnson & Johnson (US), AstraZeneca plc (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic A/S (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec, Ltd. (India), Biological E Limited (India), Bharat Biotech Ltd. (India), Novavax Inc. (US), FSUE NPO Microgen (Russia), Sinovac Biotech, Ltd. (China), Incepta Vaccine Limited (Bangladesh), Valneva SE (France), VBI Vaccines (US), PT Bio Farma (Persero) (Indonesia), Inovio Pharmaceuticals Inc. (US), Chongqing Zhifei Biological Products Co., Ltd. (China), Indian Immunologicals Limited (India)..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 9.50% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Vaccines include
- Growing prevalence of emerging and re-emerging infectious diseases
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Vaccines in 2022.
